In the present prospective study, 68Ga-PSMA-11 PET/CT accurately localized the primary prostatic lesion and metastasis in treatment-naïve prostate cancer patients, and significantly improved detection rate of the malignant lesions in patients with mCRPC, even when PSA levels were low. This evidence concerns the gene FOLH1 and prostate cancer.